Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Johnson & Johnson deal still on track after FTC (Federal Trade Commission) request:

This article was originally published in Clinica

Executive Summary

Johnson & Johnson still expects to close its $25.4bn acquisition of Guidant during the third quarter of 2005, it said after the US Federal Trade Commission requested additional information from the companies. Close scrutiny by the FTC was expected, because J&J's Cordis unit and Guidant both make stents. Cordis sells the Cypher drug-eluting stent, and Guidant is developing a rival product. The nature of the information requested was not disclosed.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts